Morningstar
•
Oct 30, 2026
Alnylam Pharmaceuticals, Inc.: Alnylam Earnings: Strong Revenue Growth Overshadowed by Slower-Than-Expected TTR Demand
Summary
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Regeneron Pharmaceuticals, Inc.
Oct 30, 2026
•
REGN
Analyst Report: Incyte Corporation
Oct 30, 2026
•
INCY
Analyst Report: Eli Lilly & Co
Oct 30, 2026
•
LLY
Market Digest: AMZN, TT, KLAC, LLY, LMT, MSFT, PSA, TMO, MA, AGNC, HLT, STRL
Oct 30, 2026
•
KLAC, TT, MSFT, HLT, LMT, MA, AGNC, TMO, LLY, STRL, AMZN, PSA
Analyst Report: Merck & Co., Inc.
Oct 29, 2026
•
MRK
